Please enter the email address you used to register, then we will send you a link to choose a new password
CELC: 133% | Celcuity Released Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial Of Gedatolisib Plus Fulvestrant With And Without Palbociclib Versus Fulvestrant In Advanced Breast Cancer
TSLA: 2% | Elon Musk Confirms Tesla As the Mystery Big-Tech That Signed $16.5 Billion Chip Contract With Samsung: 'I Will Walk The Line Personally' To Boost Progress (UPDATED)
ATAI: -20% | ATAI Life Sciences shares are trading lower after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.
Posted In: ATAI CELC TSLA